Fig. 7: RNA-seq data identified E2F2 and EZH2 as the downstream targets of BRPF1.
From: Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer
a RNA-seq identified differentially expressed genes in MHCC97L and Hep3B cells treated with 10 μM GSK5959 for 24 h. b KEGG pathway analysis of the common downregulated genes from the RNA-seq results. c GSK5959 treatment selectively led to reduced expression of key oncogenes essential for cancer growth and progression. d The mRNA expression levels of E2F2 and EZH2 were downregulated by GSK5959 treatment after 24 h in MHCC97L and Hep3B. e GSK5959 inhibited the protein levels of E2F2 and EZH2 in a dose-dependent manner after 5-day treatment. Error bars indicate mean ± SD. Data were compared by independent t-test. Results were repeated at least three times. **P < 0.01, ***P < 0.001, ****P < 0.0001 vs mock as indicated.
